{"id":1004037,"date":"2026-09-16T16:04:35","date_gmt":"2026-09-16T20:04:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-and-sobi-announce-partnership-is-now-effective-following-completion-of-closing-conditions\/"},"modified":"2026-09-16T16:04:35","modified_gmt":"2026-09-16T20:04:35","slug":"innate-and-sobi-announce-partnership-is-now-effective-following-completion-of-closing-conditions","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-and-sobi-announce-partnership-is-now-effective-following-completion-of-closing-conditions\/","title":{"rendered":"Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><b><i>The partnership between Sobi and Innate is now effective, following expiration of the anti-trust waiting periods and completion of other conditions<\/i><\/b><\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li><b><i>Transaction closing triggers the USD 75 million upfront payment and marks the initiation of the TELLOMAK-3 confirmatory Phase 3 study, with first patient expected in Q1 2027<\/i><\/b><\/li>\n<\/ul>\n<p>MARSEILLE, France&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nRegulatory News:<\/p>\n<p>\nInnate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) today announced that the <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.innate-pharma.com%2Fmedia%2Fall-press-releases%2Finnate-pharma-enters-strategic-partnership-sobi-license-lacutamab-t-cell-lymphoma&amp;esheet=54605558&amp;newsitemid=20260916899247&amp;lan=en-US&amp;anchor=previously+announced&amp;index=1&amp;md5=a3f3c988f82c1daf9f41d4ab9bde64f6\">previously announced<\/a> strategic partnership with Sobi is now effective following the expiration of applicable antitrust waiting periods and completion of other conditions.<\/p>\n<p>\nAs announced on August 10, 2026, Innate Pharma entered a strategic partnership with Sobi to license lacutamab in T-cell lymphoma. Transaction closing triggers the USD 75 million upfront payment and marks the initiation of the TELLOMAK-3 confirmatory Phase 3 study, with first patient expected in Q1 2027.<\/p>\n<p>\nUnder the agreement, Innate is conducting the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma. The TELLOMAK-3 study will subsequently support applications for full approvals in key jurisdictions in S\u00e9zary syndrome and mycosis fungoides, the most common subtype. Sobi will receive exclusive global rights to commercialize lacutamab upon potential accelerated approval and will be eligible to assume full global development rights following positive Phase 3 results.<\/p>\n<p><b>About Innate Pharma<\/b><\/p>\n<p>\nInnate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise in antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.<\/p>\n<p>\nInnate Pharma is advancing a portfolio of differentiated potential first- and\/or best-in-class assets, focused on areas of high unmet medical need. Its proprietary pipeline is centered on antibody-drug conjugates (ADCs), led by IPH4502, a differentiated Nectin-4 ADC in clinical development for solid tumors, and supported by a preclinical portfolio of next-generation ADC candidates. In parallel, Innate is advancing two partnered late-stage assets: lacutamab, developed with Sobi for T-cell lymphomas, and monalizumab, developed with AstraZeneca for non-small cell lung cancer (NSCLC).<\/p>\n<p>\nInnate Pharma has established collaborations with leading biopharmaceutical companies, including Sobi, Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.<\/p>\n<p>\nHeadquartered in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.<\/p>\n<p>\nLearn more about Innate Pharma at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.innate-pharma.com%2F&amp;esheet=54605558&amp;newsitemid=20260916899247&amp;lan=en-US&amp;anchor=www.innate-pharma.com&amp;index=2&amp;md5=252f70a71518a0bcce8bbf350705c138\">www.innate-pharma.com<\/a> and follow us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Finnate-pharma%2F&amp;esheet=54605558&amp;newsitemid=20260916899247&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=3&amp;md5=1169945b5979887c595ab1fe457a3b7f\">LinkedIn<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2FInnatePharma&amp;esheet=54605558&amp;newsitemid=20260916899247&amp;lan=en-US&amp;anchor=X&amp;index=4&amp;md5=9c15c57876706d59051d203ca0757d42\">X<\/a>.<\/p>\n<p><b>Information about Innate Pharma shares<\/b><\/p>\n<p>\nISIN code: FR0010331421<br \/>\n<br \/>Ticker code: Euronext Paris: IPH | Nasdaq: IPHA<br \/>\n<br \/>LEI: 9695002Y8420ZB8HJE29<\/p>\n<p><b>Disclaimer on forward-looking information and risk factors<\/b><\/p>\n<p>\nFor a discussion of risks and uncertainties, please refer to the Risk Factors (\u201cFacteurs de Risque&#8221;) section of the Universal Registration Document filed with the French Financial Markets Authority (\u201cAMF\u201d), which is available on the AMF website <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.amf-france.org&amp;esheet=54605558&amp;newsitemid=20260916899247&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.amf-france.org&amp;index=5&amp;md5=d56e3521309f7eb06177f7ace83d9318\">http:\/\/www.amf-france.org<\/a> or on Innate Pharma\u2019s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (\u201cSEC\u201d), including the Company\u2019s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company\u2019s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.<\/p>\n<p>\nThis press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260916899247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260916899247\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260916899247\/en\/<\/a><\/span><\/p>\n<p>\nSt\u00e9phanie Cornen<br \/>\n<br \/>VP, Investor Relations &amp; Corporate Communications<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:stephanie.cornen@innate-pharma.fr\">stephanie.cornen@innate-pharma.fr<\/a><\/p>\n<p>\nInvestor Relations<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investors@innate-pharma.fr\">investors@innate-pharma.fr<\/a><\/p>\n<p>\nMedia<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:communication@innate-pharma.fr\">communication@innate-pharma.fr<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Europe United States North America France<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology Health Clinical Trials Research Science Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260916899247\/en\/1245155\/3\/INNATEvertnoirDS.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions The partnership between Sobi and Innate is now effective, following expiration of the anti-trust waiting periods and completion of other conditions Transaction closing triggers the USD 75 million upfront payment and marks the initiation of the TELLOMAK-3 confirmatory Phase 3 study, with first patient expected in Q1 2027 MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211; Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) today announced that the previously announced strategic partnership with Sobi is now effective following the expiration of applicable antitrust waiting periods and completion of other conditions. As announced on August 10, 2026, Innate Pharma entered a strategic partnership with Sobi to license &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/innate-and-sobi-announce-partnership-is-now-effective-following-completion-of-closing-conditions\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1004037","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/innate-and-sobi-announce-partnership-is-now-effective-following-completion-of-closing-conditions\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions The partnership between Sobi and Innate is now effective, following expiration of the anti-trust waiting periods and completion of other conditions Transaction closing triggers the USD 75 million upfront payment and marks the initiation of the TELLOMAK-3 confirmatory Phase 3 study, with first patient expected in Q1 2027 MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211; Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) today announced that the previously announced strategic partnership with Sobi is now effective following the expiration of applicable antitrust waiting periods and completion of other conditions. As announced on August 10, 2026, Innate Pharma entered a strategic partnership with Sobi to license &hellip; Continue reading &quot;Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/innate-and-sobi-announce-partnership-is-now-effective-following-completion-of-closing-conditions\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-16T20:04:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260916899247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-and-sobi-announce-partnership-is-now-effective-following-completion-of-closing-conditions\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-and-sobi-announce-partnership-is-now-effective-following-completion-of-closing-conditions\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions\",\"datePublished\":\"2026-09-16T20:04:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-and-sobi-announce-partnership-is-now-effective-following-completion-of-closing-conditions\\\/\"},\"wordCount\":651,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-and-sobi-announce-partnership-is-now-effective-following-completion-of-closing-conditions\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260916899247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-and-sobi-announce-partnership-is-now-effective-following-completion-of-closing-conditions\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-and-sobi-announce-partnership-is-now-effective-following-completion-of-closing-conditions\\\/\",\"name\":\"Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-and-sobi-announce-partnership-is-now-effective-following-completion-of-closing-conditions\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-and-sobi-announce-partnership-is-now-effective-following-completion-of-closing-conditions\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260916899247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-09-16T20:04:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-and-sobi-announce-partnership-is-now-effective-following-completion-of-closing-conditions\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-and-sobi-announce-partnership-is-now-effective-following-completion-of-closing-conditions\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-and-sobi-announce-partnership-is-now-effective-following-completion-of-closing-conditions\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260916899247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260916899247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-and-sobi-announce-partnership-is-now-effective-following-completion-of-closing-conditions\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-and-sobi-announce-partnership-is-now-effective-following-completion-of-closing-conditions\/","og_locale":"en_US","og_type":"article","og_title":"Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions - Market Newsdesk","og_description":"Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions The partnership between Sobi and Innate is now effective, following expiration of the anti-trust waiting periods and completion of other conditions Transaction closing triggers the USD 75 million upfront payment and marks the initiation of the TELLOMAK-3 confirmatory Phase 3 study, with first patient expected in Q1 2027 MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211; Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) today announced that the previously announced strategic partnership with Sobi is now effective following the expiration of applicable antitrust waiting periods and completion of other conditions. As announced on August 10, 2026, Innate Pharma entered a strategic partnership with Sobi to license &hellip; Continue reading \"Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-and-sobi-announce-partnership-is-now-effective-following-completion-of-closing-conditions\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-16T20:04:35+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260916899247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-and-sobi-announce-partnership-is-now-effective-following-completion-of-closing-conditions\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-and-sobi-announce-partnership-is-now-effective-following-completion-of-closing-conditions\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions","datePublished":"2026-09-16T20:04:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-and-sobi-announce-partnership-is-now-effective-following-completion-of-closing-conditions\/"},"wordCount":651,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-and-sobi-announce-partnership-is-now-effective-following-completion-of-closing-conditions\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260916899247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-and-sobi-announce-partnership-is-now-effective-following-completion-of-closing-conditions\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-and-sobi-announce-partnership-is-now-effective-following-completion-of-closing-conditions\/","name":"Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-and-sobi-announce-partnership-is-now-effective-following-completion-of-closing-conditions\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-and-sobi-announce-partnership-is-now-effective-following-completion-of-closing-conditions\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260916899247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-09-16T20:04:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-and-sobi-announce-partnership-is-now-effective-following-completion-of-closing-conditions\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/innate-and-sobi-announce-partnership-is-now-effective-following-completion-of-closing-conditions\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-and-sobi-announce-partnership-is-now-effective-following-completion-of-closing-conditions\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260916899247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260916899247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-and-sobi-announce-partnership-is-now-effective-following-completion-of-closing-conditions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1004037","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1004037"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1004037\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1004037"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1004037"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1004037"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}